Regardless, the observation of RCRC as less responsive to anti-EGFR than anti-VEGF therapies [36] is reflected in the European Society for Molecular Oncology (ESMO) Clinical Practice Guidelines for CRC treatment, where RCRC and RAS-mutant patients are recommended combination therapies inclusive of bevacizumab (anti-VEGF), while LCRC, RAS-wildtype patients are recommended anti-EGFR therapies [37]. Here, EGFR is linked to colorectal carcinoma.